Displaying 1 - 8 of 8
| Active Ingredient | ARTESUNATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. Artesunate for Injection is indicated for the initial treatment of severe malaria in adult and pediatric patients. Treatment of severe malaria with Artesunate for Injection should always be f More ... |
| Caution | Gastrointestinal disturbances, pruritus and rash, dizziness, headache, tinnitus, neutropenia, elevated liver enzyme values, and ECG abnormalties including prolongation of the QT interval. |
| Dose Range | Oral: 4 mg/kg once daily , for 3 days. IM or IV: 2.4 mg/kg repeated after 12 and 24 hours and then once daily thereafter, transferring to an appropriate oral regimen after at least 24 hours. |
| Drug Interactions | |
| Pregnancy | Severe or complicated falciparum malaria is associated with a high risk of fatal More ... |
| Breast Feeding |
| Active Ingredient | CHLOROQUINE PHOSPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Acute and prophylactic treatment of malaria. Active rheumatoid arthritis and Systemic and discoid lupus erythematosus |
| Caution | For prophylaxis, drug should be taken on the same day each week. Nausea, vomiting, abdominal cramps, blurred vision. caution is recommended in patients with risk factors for cardiac events and th More ... |
| Dose Range | 1g to start, 500mg in 6 hours and 500mg daily for 2 days. Prophylaxis: 500mg per week, 1 week before exposure and continuing throughout and for 4 week after exposure. |
| Drug Interactions |
Avoid taking an antacid or Kaopectate (kaolin-pectin) within 4 hours before or 4 hours after chloroquine. Avoid alcohol. |
| Pregnancy | Benefit of use in prophylaxis and treatment in malaria outweighs risk. |
| Breast Feeding | Present in breast milk and breast-feeding should be avoided when used to treat r More ... |
| Active Ingredient | CHLOROQUINE SULPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | HYDROXYCHLOROQUINE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Used in both the treatment and sup p ression of malaria, as well for the treatment of rheumatoid arthritis and sy stemic lup us ery thematosus. |
| Caution |
Adverse effects following short -term therap y include rash, vertigo, transient headache and gastrointestinal comp laints such as nausea, vomiting, diarrhea and abdominal cramps. Ocular to More ... |
| Dose Range | Lupus: Initially , 400mg 1-2 times daily until remission. Maintenance: 200-400mg daily . Take with food or milk. |
| Drug Interactions | Healthcare professionals are reminded to consider the benefits and risks of co-prescribing systemic azithromycin, or other systemic macrolides, with hydroxychloroquine, if this cannot be avoided , pat More ... |
| Pregnancy | It is not necessary to withdraw an antimalarial drug during pregnancy if the rhe More ... |
| Breast Feeding | It is advised to avoid due to the potential risk of toxicity in the infant. moni More ... |
| Active Ingredient | MEFLOQUINE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Mefloquine is indicated for the prophylaxis and the treatment of mild to moderate malaria caused by Plasmodium vivax and susceptible strains of Plasmodium falciparum. |
| Caution | Anorexia, vomiting, nausea, diarrhoea, dizziness ,sleep disturbance, panic attacks, sudden on set of anxiety , restlessness, irritability, confusion, persistently abnormal heart beat, palpitations, b More ... |
| Dose Range | Acute disease: 5 tablets (1250mg) should be given as a single oral dose or 750mg initially followed by 500mg given 12 hours later. Prophylaxis: 250mg per week prior to departure (commence 1-3weeks prior to travel), during period in endemic area and 4 weeks after return. Alternatively : 250mg for 3 days followed by 250mg weekly (in cases where a loading dose is required). (NB: 250mg M efloquine HCL = 228mg of the base). |
| Drug Interactions | When mefloquine is used for prevention or chemoprophylaxis of malaria in travelers, possible effects of mefloquine on other drugs these individuals are receiving (especially anticoagulants and antidia More ... |
| Pregnancy | Manufacturer advises avoid unless the potential benefit outweighs the risk parti More ... |
| Breast Feeding | Present in milk but risk to infant minimal. |
| Active Ingredient | PRIMAQUINE PHOSPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. Used with chloroquine. |
| Caution | To decrease G.I. side effects. Monitor for hematological effects. |
| Dose Range | 15mg (base) daily for 14 day s. M ay be used for up to 21 day s. Take with food. |
| Drug Interactions | |
| Pregnancy | The manufacturer states that primaquine should be avoided during pregnancy. Risk More ... |
| Breast Feeding |
| Active Ingredient | QUININE BISULPHATE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | |
| Caution | |
| Dose Range | |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | QUININE DIHYDROCHLORIDE |
| Therapeutic Class | ANTIMALARIALS |
| Indications | Malaria. |
| Caution | Phototoxicity , ototoxicity , drug fever. |
| Dose Range | Adult: 600mg every 8 hours for 7 days. Pediatric: 10mg/kg 3 times daily for 7 days. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |